enlicitide decanoate

Sponsor Merck & CO INC. · listed as MRK

READOUT Phase 3 Confidence: medium Source: clinicaltrials

enlicitide decanoate is a clinical-stage drug asset sponsored by Merck & CO INC., listed as MRK. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2, 2026 (day precision, medium confidence), tied to trial NCT07216482. The asset is in Phase 3 and currently active not recruiting, studied in Hyperlipidemia. It appears across 4 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2026-12-02

As disclosedDec 2, 2026

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT07216482

PhasePHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorMerck Sharp & Dohme LLC

Listed asMRK

Condition(s)Hyperlipidemia

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More MRK catalysts